THE GLOBAL IN VITRO DIAGNOSTICS MARKET WAS VALUED AT USD 105.23 BILLION IN 2022 AND IS EXPECTED TO REACH USD 127.56 BILLION BY 2028, GROWING AT A CAGR OF 3.26% DURING THE FORECAST PERIOD.

The In Vitro Diagnostics Market Size, Share, & Trends Analysis Report By

  • Product & Services: Reagents and Consumables, Instruments/ Analyzers & Software, and Services
  • Technology: Immuno and Clinical Chemistry, Molecular Diagnostics, Hematology, Microbiology and Cytology, and Other
  • Application: Infectious Diseases, Diabetes, Cardiology, Oncology, Autoimmune Diseases, Nephrology, Drug Testing, and Others
  • End-Users: Standard Reference Labs, Hospital-Affiliated Labs, Individuals, Clinics, and Others
  • Geography: North America, Europe, APAC, Latin America, and Middle East & Africa

Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2023–2028

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

402 Pages

icon-table

239 Tables

icon-chart

156 Charts

icon-region

5 Regions

icon-country

22 Countries

icon-company

90 Companies

icon-market

5 Market Segment

GLOBAL IN-VITRO DIAGNOSTICS MARKET REPORT SCOPE

Report Attribute Details
Market Size (2028) USD 127.56 Billion
MARKET SIZE (2022) USD 105.23 Billion
CAGR (2022-2028) 3.26%
BASE YEAR 2022
FORECAST YEAR 2023-2028
SEGMENTS BY Product & Services, Technology, Application, End-Users, and Geography
LARGEST REGIONAL MARKET North America
GEOGRAPHIC ANALYSIS North America, Europe, APAC, Latin America, and Middle East & Africa
KEY VENDORS Abbott, Danaher, F. Hoffmann-La Roche, Siemens Healthineers, and Thermo Fisher Scientific

MARKET INSIGHTS

The global in vitro diagnostics market size crossed USD 105.23 billion in 2022 and is expected to reach USD 127.56 billion by 2028, growing at a CAGR of 3.26%. The IVD market offers advanced, cost-effective, and fast tools that enable precise diagnosis and point-of-care testing or self-testing. The market has moved from conventional instruments to advanced analyzers that need a small volume of samples and high-throughput screening methodologies. These advances, combined with AI and cloud technology, revolutionize the in vitro diagnostics market. The low-volume sample analysis, automation, high-throughput analysis, rapid analysis times, small footprint, low cost, portability, and disposability are key trends in the IVD market.

IVD are clinical tests that analyze samples taken from people and deliver treatments for specific diseases. Globally, the burden of chronic infectious diseases accelerates the demand for advanced diagnostic services that drive the growth of the in vitro diagnostics market. In the US, the growth of the in vitro diagnostics market is mostly driven by the country's expenditure and awareness of chronic and infectious diseases. Access to diagnosis and care services across the US is significantly higher than in developed countries. With the growing preference for early detection and diagnosis of chronic and infectious diseases, the country's demand for IVD solutions increased. Other than COVID-19 and monkeypox, other infectious diseases, such as HIV, HSV, and chlamydia, are the leading infectious diseases that drive the demand for IVD diagnosis in the country.

MARKET TRENDS & OPPORTUNITIES

Advances in Molecular Diagnostics Transforming the Future of Healthcare
The healthcare industry witnessed high development and growth in invitro diagnostics over the past decade. Advances in molecular diagnostics are dramatically improving medical treatment outcomes in current times. Due to drug failure in clinical trials and regulatory barriers, bio-pharmaceutical companies are turning toward new medical solutions at the molecular level and molecular diagnostics. In addition, next-generation sequencing and clustered regularly interspaced short palindromic repeats (CRISPER) technology significantly improve molecular diagnostics for oncology and infectious diseases care. Such factors are expected to lead the in vitro diagnostics market in the future.

Increasing Product Launches & Mergers & Acquisitions in IVD
IVD diagnostics is among the biggest industries to witness several product launches in recent years. The increasing demand for new diagnostics tests forces us to develop new solutions. Currently, the IVD players are operating in a world that designs, develops, manufactures, and sells best-in-class solutions. COVID-19 is one of the best periods where several companies have come forward to develop rapid test kits to detect coronavirus.

In the first half of 2021, IVD companies reported high revenues due to COVID-19 testing. However, in the year's second half, many companies experienced low demand for COVID-19 testing, resulting in decreased COVID-19 product revenue. In the same period, to increase the production and expansion of distribution networks, IVD companies adopted M&A strategies. To prepare for COVID-19, some major and emerging IVD companies have turned to M&As to increase their diagnostic testing portfolio. These acquisitions witnessed the in vitro diagnostics market expansion and portfolio expansion.

A large patient population with chronic and infectious diseases drives the demand for IVD solutions and fuels market growth.
Chronic diseases such as cancer, diabetes, cardiovascular diseases, and others are public health concerns worldwide, resulting in high demand for diagnostic services. In addition, infectious diseases, such as HIV, COVID-19, influenza, staphylococcus, respiratory syncytial virus, and others, pose significant demand for diagnostic services and fuel market growth.

The adoption of advanced technologies in IVD drives significant IVD testing worldwide without experiencing the burden of time and cost. Moreover, they have increased the efficiency of diagnostics and delivered the most accurate results that accelerate market growth. Advances, such as a new generation of IVD products with AI and the digital platform, provide newer dimensions in the global in vitro diagnostics market.

SEGMENTATION INSIGHTS

INSIGHTS BY PRODUCTS AND SERVICES
The reagent and consumables are the largest segments, accounting for 66.47% of the global in vitro diagnostics market in 2022. Reagents and consumables are used in IVD procedures as a medium and transporter of specimens of patients with medical conditions for diagnosis, treatments, and monitoring. The reoccurring use of reagents and consumables is driving the market growth. Innovation in consumables, especially reagents, is low compared to analyzers. Some companies do come up with new types of reagents for unique products. For instance, Sysmex, a Japanese company, developed a concentrated reagent for hematology analyzers. These concentrated reagents are gaining traction in the market, especially in developed countries. This is helping the company to gain market share. End-users are shifting toward concentrated reagents, which have more benefits than conventional reagents.

INSIGHTS BY TECHNOLOGY
The global in vitro diagnostics market is segmented into immuno & clinical chemistry, molecular testing, hematology, microbiology & cytology, point- and others by technology. In 2022, the immune & clinical chemistry segment accounted for 45.26% market share of the global IVD market and dominated the other segments. Immunoassay and clinical chemistry are technologies that experience high usage in IVD. These technologies are mostly used to diagnose infectious and chronic diseases that significantly burden global healthcare services. The patient population with chronic and infectious diseases drives the segmental growth of immunochemistry-based IVD solutions. Furthermore, clinical chemistry has wide applications in detecting cancer, diabetes, heart disease, renal disease, liver disorders, and other health conditions that accelerate segmental growth.

INSIGHTS BY APPLICATION
In 2022, in vitro diagnostics applications for infectious diseases accounted for 46.95% market share. The global IVD market application is segmented into infectious diseases, diabetes, cardiology, oncology, autoimmune diseases, nephrology, drug testing, and others by application. During the COVID-19 pandemic, more than 3 to 4 billion tests were conducted worldwide, which fueled the growth of the in-vitro diagnostics market. In addition, HIV, influenza, respiratory syncytial virus, and other infectious diseases drive the demand for IVD and boost industry growth. With the increasing burden of infectious diseases, the demand for diagnosis and treatment continues to rise, thus driving the demand for IVD solutions. In recent years, the development in technologies and increasing integration of new technologies for infectious disease diagnosis have led the market to witness high revenue generation through the infectious diseases segment.

INSIGHTS BY END-USERS
The standard reference labs dominated the end-user segment in the global in vitro diagnostics market and was valued at USD 36 billion in 2022 and is expected to grow impressively by 2028. Standard reference laboratories offer several types of IVD services. In recent years, standard reference laboratories have rapidly expanded in LMICs to offer numerous tests and deliver high market growth through adopting new technologies and product offerings. Standard reference laboratories expand their network in a particular region or concentrated areas and deliver easy access to diagnostic services at affordable prices. In addition, the broad range of diagnosis services increases access to several tests that attract a high consumer base and generate significant revenue. In 2022, the standard reference labs segment accounted for 34.21% of the global IVD market.

The global in-vitro diagnostics market by hospital-affiliated labs was valued at USD 28.54 billion in 2022. Hospitals are the primary source and first point of contact for disease diagnosis and cure. In contrast, hospital-associated laboratories account for the high number of IVD practices and drive segmental growth. Globally, the number of hospitals and associated laboratories, growing infrastructure, and increasing healthcare expenditure are some factors that increase the demand for IVD practices through hospitals.

GEOGRAPHICAL ANALYSIS

In 2022, North America dominated the global IVD market accounting for a 39.90% share. A large patient population base with high healthcare expenditures accelerates the region's market growth. In addition, the awareness of disease diagnosis, such as point-of-care, early detection, and preventive health check-ups, are some factors that majorly and positively impact the industry growth in the region. More than 60% to 80% of the regional population have chronic conditions that demand diagnostics services. Expenditure on healthcare services in the region accounted for approximately USD 4.3 trillion and above in 2021, which grew by 2.7% from 2020, indicating a high potential for market growth. Some leading companies, such as Abbott, BD, Bio-Rad Laboratories, and Biomerieux SA, have higher market penetration in the region, especially in the US. They are increasing access to IVD components and accounting for high revenue generation in the country.

Europe is one of the leading and major regions for the IVD market, which accounts for a significant demand for IVD solutions. The factors responsible for the increasing demand for IVD solutions are the growing aging population in the region, with chronic and infectious diseases driving the high demand for IVD solutions. Across Europe, more than 25,000 pathologists are available, while the UK accounts for 40 pathologists per million population. Germany and France accounted for 20 to 29 pathologists per million population. Europe's in vitro diagnostics market is expected to reach USD 31.41 billion by 2028.

COMPETITIVE LANDSCAPE

The leading players in the global in vitro diagnostics market are F Hoffmann-La Roche, Abbott, Thermo Fisher Scientific, and Siemens Healthineers, which are competing with rapidly emerging market players. Vendors are increasing their industry market share through inorganic growth and a constant product launch, helping the vendors acquire new customers. Abbot is one of the leading companies in the global in vitro diagnostics market and is a pioneer in point-of-care diagnostics with a comprehensive portfolio of tests and systems. Its diagnostic products segment offers core laboratory analyzers and biomarkers (clinical chemistry), immunoassay, hematology, and transfusion. In 2021, the company achieved around USD 15.6 billion in revenue, respectively.

Recent Developments in The Global In Vitro Diagnostics Market

  • In March 2020, Abbott’s rapid diagnostic segment launched a molecular test solution to detect COVID-19 with its ID NOW rapid POC in the US.
  • Hoffmann-La Roche invested significantly in R&D activities to develop innovative IVD test solutions. For instance, in FY2019, the company invested about $12.86 billion in R&D activities.
  • In July 2019, Siemens Healthineers completed the acquisition of Minicare B.V. Minicare is developing technology for point-of-care immunoassay testing. The business is being integrated into the Diagnostics segment and will allow Siemens Healthineers to strengthen its portfolio in the rapid diagnostics domain.

Frequently Asked Questions

How big is the In Vitro Diagnostics Market?

The global in vitro diagnostics market size was valued at USD 105.23 billion in 2022 and is expected to reach USD 127.56 billion by 2028.

What is the growth rate of the in vitro diagnostics market?

The global in vitro diagnostics market share is growing at a CAGR of 3.26% from 2022-2028.

Who are the key players in the global in vitro diagnostics market?

Abbott, Danaher, F. Hoffmann-La Roche, Siemens Healthineers, and Thermo Fisher Scientific are the major players in the global in-vitro diagnostics market.

Which region holds the most significant global in vitro diagnostics market share?

In 2022, North America accounted for the largest global in-vitro diagnostics market accounting for a 39.90% share. Awareness of primary care and point-of-care for those disease conditions fuel the acceptance of IVD solutions and services in the region.

What are the growing trends in the in vitro diagnostics market?

Advances in molecular diagnostics are transforming the future of healthcare, increasing demand for companion diagnostics in IVD, and increasing product launches & mergers & acquisitions are trends in the in-vitro diagnostics market.

Download Free Sample

The in vitro diagnostics market is expected to grow at a CAGR of approximately 3.26% from 2022 to 2028.

The following factors are likely to contribute to the growth of the in vitro diagnostics market during the forecast period:

  • Presence of a Significant Patient Population
  • Adoption of Advanced Technologies in IVD
  • COVID-19 Impacts on IVD Acceptance

Base Year: 2022

Forecast Year: 2023-2028

The report considers the present scenario of the global in vitro diagnostics market and its market dynamics for 2023−2028. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the industry. It also profiles and analyzes leading companies and several other prominent companies operating in the industry.

Key Company Profiles

  • Abbott
    • Business Overview
    • Product Offerings
    • Key Strategies
    • Key Strengths
    • Key Opportunities
  • Danaher
  • F. Hoffmann-La Roche
  • Siemens Healthineers
  • Thermo Fisher Scientific

Other Prominent Vendors

  • Atomo Diagnostics
    • Business Overview
    • Product Offerings
  • Accelerate Diagnostics
  • Agilent Technologies
  • altona Diagnostics
  • Amoy Diagnostics
  • ARKRAY
  • AccuBioTech
  • Agappe Diagnostics
  • BD
  • Bio-Rad Laboratories
  • Balio diagnostics
  • B&E BIO-TECHNOLOGY
  • BIOMÉRIEUX
  • bioLytical Laboratories
  • Biosynex
  • Biocartis
  • Biocept
  • Biohit Oyj
  • Biomerica
  • Biosystems
  • Bioway Biological Technology
  • Boule Diagnostics
  • Cupid Limited
  • CareDx
  • Chembio Diagnostics
  • CLINDIAG SYSTEMS
  • CONTEC MEDICAL SYSTEMS
  • Convergent Technologies
  • CPC Diagnostics
  • CPM Scientifica
  • CellaVision
  • DIALAB
  • Dexcom
  • DiaSorin
  • Diagon
  • Diatron
  • DIRUI
  • Drucker Diagnostics
  • EDAN Instruments
  • EKF Diagnostics Holdings
  • ELITechGroup
  • Erba Diagnostics
  • Genetron Holdings
  • Genrui Biotech
  • Hologic
  • High Technology
  • HORIBA
  • Linear Chemicals
  • Illumina
  • INTEC
  • J. Mitra & Co.
  • Kilpest India Limited
  • Maccura Biotechnology
  • Medsource Ozone Biomedicals
  • Meril Life Sciences
  • MP Biomedicals
  • Nanjing Synthgene Medical Technology
  • NIHON KOHDEN
  • Norma Instruments
  • NOWDiagnostics
  • Ortho Clinical Diagnostics
  • OPKO Health
  • OraSure Technologies
  • Perkin Elmer
  • Prestige Diagnostics
  • QIAGEN
  • Quidel
  • Sysmex
  • Salofa Oy
  • SEASUN BIOMATERIALS
  • Sekisui Diagnostics
  • SFRI
  • Shenzhen Dymind Biotechnology
  • Shenzhen iCubio Biomedical Technology
  • Shenzhen Mindray Bio-Medical Electronics
  • SHENZHEN PROKAN ELECTRONICS
  • Shenzhen Landwind Medical
  • Sinocare
  • SPINREACT
  • SureScreen Diagnostics
  • The Binding Site Group
  • Trinity Biotech
  • Trivitron Healthcare
  • Xiamen Biotime Biotechnology
  • Zhejiang Orient Gene Biotech

Segmentation By Product & Services

  • Reagents and Consumables
  • Instruments/ Analyzers & Software
  • Services

Segmentation By Technology

  • Immuno and Clinical Chemistry
  • Molecular Diagnostics
  • Hematology
  • Microbiology and Cytology
  • Others Technology

Segmentation By Application

  • Infectious Diseases
  • Diabetes
  • Cardiology
  • Oncology
  • Autoimmune Diseases
  • Nephrology
  • Drug Testing
  • Others

Segmentation By End-Users

  • Standard Reference Labs
  • Hospital-Affiliated Labs
  • Individuals
  • Clinics
  • Others

Segmentation by Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • Russia
    • Spain
    • Italy
    • UK
  • APAC
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Malaysia
    • Singapore
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • South Africa

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

 

4 SCOPE & COVERAGE

4.1 MARKET DEFINITION

4.1.1 INCLUSIONS

4.1.2 EXCLUSIONS

4.1.3 MARKET ESTIMATION CAVEATS

4.2 BASE YEAR

4.3 SCOPE OF THE STUDY

4.3.1 MARKET BY PRODUCT & SERVICES:

4.3.2 MARKET BY TECHNOLOGY

4.3.3 MARKET BY APPLICATION

4.3.4 MARKET BY END-USERS

4.3.5 MARKET SEGMENTATION BY GEOGRAPHY

 

5 REPORT ASSUMPTIONS & CAVEATS

5.1 KEY CAVEATS

5.2 CURRENCY CONVERSION

5.3 MARKET DERIVATION

 

6 MARKET AT A GLANCE

7 PREMIUM INSIGHTS

7.1 OVERVIEW

 

8 INTRODUCTION

8.1 OVERVIEW

 

9 MARKET OPPORTUNITIES & TRENDS

9.1 ADVANCES IN MOLECULAR DIAGNOSTICS TRANSFORMING THE FUTURE OF HEALTHCARE

9.2 INCREASED DEMAND FOR COMPANION DIAGNOSTICS IN IVD

9.3 INCREASING PRODUCT LAUNCHES & MERGERS & ACQUISITIONS IN IVD

 

10 MARKET GROWTH ENABLERS

10.1 PRESENCE OF A SIGNIFICANT PATIENT POPULATION

10.2 ADOPTION OF ADVANCED TECHNOLOGIES IN IVD

10.3 COVID-19 IMPACT ON IVD MARKET

 

11 MARKET RESTRAINTS

11.1 STRINGENT REGULATIONS AND ASSOCIATED CHALLENGES

11.2 HIGH COST OF IVD

11.3 LACK OF ACCESS TO DIAGNOSTIC SERVICES AND ASSOCIATED CHALLENGES

 

12 MARKET LANDSCAPE

12.1 MARKET OVERVIEW

12.1.1 INSIGHT BY PRODUCT & SERVICES

12.1.2 INSIGHT BY TECHNOLOGY

12.1.3 INSIGHT BY APPLICATION

12.1.4 INSIGHT BY END-USERS

12.1.5 INSIGHT BY GEOGRAPHY

12.2 MARKET SIZE & FORECAST

12.3 FIVE FORCES ANALYSIS

12.3.1 THREAT OF NEW ENTRANTS

12.3.2 BARGAINING POWER OF SUPPLIERS

12.3.3 BARGAINING POWER OF BUYERS

12.3.4 THREAT OF SUBSTITUTES

12.3.5 COMPETITIVE RIVALRY

 

13 PRODUCT & SERVICES

13.1 MARKET SNAPSHOT & GROWTH ENGINE

13.2 MARKET OVERVIEW

13.3 REAGENTS AND CONSUMABLES

13.3.1 MARKET OVERVIEW

13.3.2 MARKET SIZE & FORECAST

13.3.3 MARKET BY GEOGRAPHY

13.4 INSTRUMENTS/ANALYZERS & SOFTWARE

13.4.1 MARKET OVERVIEW

13.4.2 MARKET SIZE & FORECAST

13.4.3 MARKET BY GEOGRAPHY

13.5 SERVICES

13.5.1 MARKET OVERVIEW

13.5.2 MARKET SIZE & FORECAST

13.5.3 MARKET BY GEOGRAPHY

 

14 TECHNOLOGY

14.1 MARKET SNAPSHOT & GROWTH ENGINE

14.2 MARKET OVERVIEW

14.3 IMMUNO & CLINICAL CHEMISTRY

14.3.1 MARKET OVERVIEW

14.3.2 MARKET SIZE & FORECAST

14.3.3 MARKET BY GEOGRAPHY

14.4 MOLECULAR DIAGNOSTICS

14.4.1 MARKET OVERVIEW

14.4.2 MARKET SIZE & FORECAST

14.4.3 MARKET BY GEOGRAPHY

14.5 HEMATOLOGY

14.5.1 MARKET OVERVIEW

14.5.2 MARKET SIZE & FORECAST

14.5.3 MARKET BY GEOGRAPHY

14.6 MICROBIOLOGY & CYTOLOGY

14.6.1 MARKET OVERVIEW

14.6.2 MARKET SIZE & FORECAST

14.6.3 MARKET BY GEOGRAPHY

14.7 OTHERS

14.7.1 MARKET OVERVIEW

14.7.2 MARKET SIZE & FORECAST

14.7.3 MARKET BY GEOGRAPHY

 

15 APPLICATION

15.1 MARKET SNAPSHOT & GROWTH ENGINE

15.2 MARKET OVERVIEW

15.3 INFECTIOUS DISEASES

15.3.1 MARKET OVERVIEW

15.3.2 MARKET SIZE & FORECAST

15.3.3 MARKET BY GEOGRAPHY

15.4 DIABETES

15.4.1 MARKET OVERVIEW

15.4.2 MARKET SIZE & FORECAST

15.4.3 MARKET BY GEOGRAPHY

15.5 CARDIOLOGY

15.5.1 MARKET OVERVIEW

15.5.2 MARKET SIZE & FORECAST

15.5.3 MARKET BY GEOGRAPHY

15.6 ONCOLOGY

15.6.1 MARKET OVERVIEW

15.6.2 MARKET SIZE & FORECAST

15.6.3 MARKET BY GEOGRAPHY

15.7 AUTOIMMUNE DISEASE

15.7.1 MARKET OVERVIEW

15.7.2 MARKET SIZE & FORECAST

15.7.3 MARKET BY GEOGRAPHY

15.8 NEPHROLOGY

15.8.1 MARKET OVERVIEW

15.8.2 MARKET SIZE & FORECAST

15.8.3 MARKET BY GEOGRAPHY

15.9 DRUG TESTING

15.9.1 MARKET OVERVIEW

15.9.2 MARKET SIZE & FORECAST

15.9.3 MARKET BY GEOGRAPHY

15.10 OTHERS

15.10.1 MARKET OVERVIEW

15.10.2 MARKET SIZE & FORECAST

15.10.3 MARKET BY GEOGRAPHY

 

16 END-USERS

16.1 MARKET SNAPSHOT & GROWTH ENGINE

16.2 MARKET OVERVIEW

16.3 STANDARD REFERENCE LABS

16.3.1 MARKET OVERVIEW

16.3.2 MARKET SIZE & FORECAST

16.3.3 MARKET BY GEOGRAPHY

16.4 HOSPITAL-AFFILIATED LABS

16.4.1 MARKET OVERVIEW

16.4.2 MARKET SIZE & FORECAST

16.4.3 MARKET BY GEOGRAPHY

16.5 INDIVIDUALS

16.5.1 MARKET OVERVIEW

16.5.2 MARKET SIZE & FORECAST

16.5.3 MARKET BY GEOGRAPHY

16.6 CLINICS

16.6.1 MARKET OVERVIEW

16.6.2 MARKET SIZE & FORECAST

16.6.3 MARKET BY GEOGRAPHY

16.7 OTHERS

16.7.1 MARKET OVERVIEW

16.7.2 MARKET SIZE & FORECAST

16.7.3 MARKET BY GEOGRAPHY

 

17 GEOGRAPHY

17.1 MARKET SNAPSHOT & GROWTH ENGINE

17.2 GEOGRAPHIC OVERVIEW

 

18 NORTH AMERICA

18.1 MARKET OVERVIEW

18.2 MARKET SIZE & FORECAST

18.3 PRODUCT & SERVICES

18.3.1 MARKET SIZE & FORECAST

18.4 TECHNOLOGY

18.4.1 MARKET SIZE & FORECAST

18.5 APPLICATION

18.5.1 MARKET SIZE & FORECAST

18.6 END-USER

18.6.1 MARKET SIZE & FORECAST

18.7 KEY COUNTRIES

18.7.1 US: MARKET SIZE & FORECAST

18.7.2 CANADA: MARKET SIZE & FORECAST

 

19 EUROPE

19.1 MARKET OVERVIEW

19.2 MARKET SIZE & FORECAST

19.3 PRODUCT & SERVICES

19.3.1 MARKET SIZE & FORECAST

19.4 TECHNOLOGY

19.4.1 MARKET SIZE & FORECAST

19.5 APPLICATION

19.5.1 MARKET SIZE & FORECAST

19.6 END-USER

19.6.1 MARKET SIZE & FORECAST

19.7 KEY COUNTRIES

19.7.1 GERMANY: MARKET SIZE & FORECAST

19.7.2 FRANCE: MARKET SIZE & FORECAST

19.7.3 RUSSIA: MARKET SIZE & FORECAST

19.7.4 SPAIN: MARKET SIZE & FORECAST

19.7.5 ITALY: MARKET SIZE & FORECAST

19.7.6 UK: MARKET SIZE & FORECAST

 

20 APAC

20.1 MARKET OVERVIEW

20.2 MARKET SIZE & FORECAST

20.3 PRODUCT & SERVICES

20.3.1 MARKET SIZE & FORECAST

20.4 TECHNOLOGY

20.4.1 MARKET SIZE & FORECAST

20.5 APPLICATION

20.5.1 MARKET SIZE & FORECAST

20.6 END-USER

20.6.1 MARKET SIZE & FORECAST

20.7 KEY COUNTRIES

20.7.1 CHINA: MARKET SIZE & FORECAST

20.7.2 JAPAN: MARKET SIZE & FORECAST

20.7.3 INDIA: MARKET SIZE & FORECAST

20.7.4 SOUTH KOREA: MARKET SIZE & FORECAST

20.7.5 AUSTRALIA: MARKET SIZE & FORECAST

20.7.6 INDONESIA: MARKET SIZE & FORECAST

20.7.7 MALAYSIA MARKET SIZE & FORECAST

20.7.8 SINGAPORE MARKET SIZE & FORECAST

 

21 LATIN AMERICA

21.1 MARKET OVERVIEW

21.2 MARKET SIZE & FORECAST

21.3 PRODUCT & SERVICES

21.3.1 MARKET SIZE & FORECAST

21.4 TECHNOLOGY

21.4.1 MARKET SIZE & FORECAST

21.5 APPLICATION

21.5.1 MARKET SIZE & FORECAST

21.6 END-USER

21.6.1 MARKET SIZE & FORECAST

21.7 KEY COUNTRIES

21.7.1 BRAZIL: MARKET SIZE & FORECAST

21.7.2 MEXICO: MARKET SIZE & FORECAST

21.7.3 ARGENTINA: MARKET SIZE & FORECAST

 

22 MIDDLE EAST & AFRICA

22.1 MARKET OVERVIEW

22.2 MARKET SIZE & FORECAST

22.3 PRODUCT & SERVICES

22.3.1 MARKET SIZE & FORECAST

22.4 TECHNOLOGY

22.4.1 MARKET SIZE & FORECAST

22.5 APPLICATION

22.5.1 MARKET SIZE & FORECAST

22.6 END-USER

22.6.1 MARKET SIZE & FORECAST

22.7 KEY COUNTRIES

22.7.1 TURKEY: MARKET SIZE & FORECAST

22.7.2 SAUDI ARABIA: MARKET SIZE & FORECAST

22.7.3 SOUTH AFRICA: MARKET SIZE & FORECAST

 

23 COMPETITIVE LANDSCAPE

23.1 COMPETITION OVERVIEW

23.2 MARKET SHARE ANALYSIS

23.2.1 ABBOTT

23.2.2 DANAHER

23.2.3 F. HOFFMANN-LA ROCHE

23.2.4 SIEMENS HEALTHINEERS

23.2.5 THERMO FISHER SCIENTIFIC

 

24 KEY COMPANY PROFILES

24.1 ABBOTT

24.1.1 BUSINESS OVERVIEW

24.1.2 PRODUCT OFFERINGS

24.1.3 KEY STRATEGIES

24.1.4 KEY STRENGTHS

24.1.5 KEY OPPORTUNITIES

24.2 DANAHER

24.2.1 BUSINESS OVERVIEW

24.2.2 PRODUCT OFFERINGS

24.2.3 KEY STRATEGIES

24.2.4 KEY STRENGTHS

24.2.5 KEY OPPORTUNITIES

24.3 F. HOFFMANN-LA ROCHE

24.3.1 BUSINESS OVERVIEW

24.3.2 PRODUCT OFFERINGS

24.3.3 KEY STRATEGIES

24.3.4 KEY STRENGTHS

24.3.5 KEY OPPORTUNITIES

24.4 SIEMENS HEALTHINEERS

24.4.1 BUSINESS OVERVIEW

24.4.2 PRODUCT OFFERINGS

24.4.3 KEY STRATEGIES

24.4.4 KEY STRENGTHS

24.4.5 KEY OPPORTUNITIES

24.5 THERMO FISHER SCIENTIFIC

24.5.1 BUSINESS OVERVIEW

24.5.2 PRODUCT OFFERINGS

24.5.3 KEY STRATEGIES

24.5.4 KEY STRENGTHS

24.5.5 KEY OPPORTUNITIES

 

25 OTHER PROMINENT VENDORS

25.1 ATOMO DIAGNOSTICS

25.1.1 BUSINESS OVERVIEW

25.1.2 PRODUCT OFFERINGS

25.2 ACCELERATE DIAGNOSTICS

25.2.1 BUSINESS OVERVIEW

25.2.2 PRODUCT OFFERINGS

25.3 AGILENT TECHNOLOGIES

25.3.1 BUSINESS OVERVIEW

25.3.2 PRODUCT OFFERINGS

25.4 ALTONA DIAGNOSTICS

25.4.1 BUSINESS OVERVIEW

25.4.2 PRODUCT OFFERINGS

25.5 AMOY DIAGNOSTICS

25.5.1 BUSINESS OVERVIEW

25.5.2 PRODUCT OFFERINGS

25.6 ARKRAY

25.6.1 BUSINESS OVERVIEW

25.6.2 PRODUCT OFFERINGS

25.7 ACCUBIOTECH

25.7.1 BUSINESS OVERVIEW

25.7.2 PRODUCT OFFERINGS

25.8 AGAPPE DIAGNOSTICS

25.8.1 BUSINESS OVERVIEW

25.8.2 PRODUCT OFFERINGS

25.9 BD

25.9.1 BUSINESS OVERVIEW

25.9.2 PRODUCT OFFERINGS

25.10 BIO-RAD LABORATORIES

25.10.1 BUSINESS OVERVIEW

25.10.2 PRODUCT OFFERINGS

25.11 BALIO DIAGNOSTICS

25.11.1 BUSINESS OVERVIEW

25.11.2 PRODUCT OFFERINGS

25.12 B&E BIO-TECHNOLOGY

25.12.1 BUSINESS OVERVIEW

25.12.2 PRODUCT OFFERINGS

25.13 BIOMÉRIEUX

25.13.1 BUSINESS OVERVIEW

25.13.2 PRODUCT OFFERINGS

25.14 BIOLYTICAL LABORATORIES

25.14.1 BUSINESS OVERVIEW

25.14.2 PRODUCT OFFERINGS

25.15 BIOSYNEX

25.15.1 BUSINESS OVERVIEW

25.15.2 PRODUCT OFFERINGS

25.16 BIOCARTIS

25.16.1 BUSINESS OVERVIEW

25.16.2 PRODUCT OFFERINGS

25.17 BIOCEPT

25.17.1 BUSINESS OVERVIEW

25.17.2 PRODUCT OFFERINGS

25.18 BIOHIT OYJ

25.18.1 BUSINESS OVERVIEW

25.18.2 PRODUCT OFFERINGS

25.19 BIOMERICA

25.19.1 BUSINESS OVERVIEW

25.19.2 PRODUCT OFFERINGS

25.20 BIOSYSTEM

25.20.1 BUSINESS OVERVIEW

25.20.2 PRODUCT OFFERINGS

25.21 BIOWAY BIOLOGICAL TECHNOLOGY

25.21.1 BUSINESS OVERVIEW

25.21.2 PRODUCT OFFERINGS

25.22 BOULE DIAGNOSTICS

25.22.1 BUSINESS OVERVIEW

25.22.2 PRODUCT OFFERINGS

25.23 CUPID LIMITED

25.23.1 BUSINESS OVERVIEW

25.23.2 PRODUCT OFFERINGS

25.24 CAREDX

25.24.1 BUSINESS OVERVIEW

25.24.2 PRODUCT OFFERINGS

25.25 CHEMBIO DIAGNOSTICS

25.25.1 BUSINESS OVERVIEW

25.25.2 PRODUCT OFFERINGS

25.26 CLINDIAG SYSTEMSA

25.26.1 BUSINESS OVERVIEW

25.26.2 PRODUCT OFFERINGS

25.27 CONTEC MEDICAL SYSTEMS

25.27.1 BUSINESS OVERVIEW

25.27.2 PRODUCT OFFERINGS

25.28 CONVERGENT TECHNOLOGIES

25.28.1 BUSINESS OVERVIEW

25.28.2 PRODUCT OFFERINGS

25.29 CPC DIAGNOSTICS

25.29.1 BUSINESS OVERVIEW

25.29.2 PRODUCT OFFERINGS

25.30 CPM SCIENTIFICA

25.30.1 BUSINESS OVERVIEW

25.30.2 PRODUCT OFFERINGS

25.31 CELLAVISION

25.31.1 BUSINESS OVERVIEW

25.31.2 PRODUCT OFFERINGS

25.32 DIALAB

25.32.1 BUSINESS OVERVIEW

25.32.2 PRODUCT OFFERINGS

25.33 DEXCOM

25.33.1 BUSINESS OVERVIEW

25.33.2 PRODUCT OFFERINGS

25.34 DIASORIN

25.34.1 BUSINESS OVERVIEW

25.34.2 PRODUCT OFFERINGS

25.35 DIAGON

25.35.1 BUSINESS OVERVIEW

25.35.2 PRODUCT OFFERINGS

25.36 DIATRON

25.36.1 BUSINESS OVERVIEW

25.36.2 PRODUCT OFFERINGS

25.37 DIRUI

25.37.1 BUSINESS OVERVIEW

25.37.2 PRODUCT OFFERINGS

25.38 DRUCKER DIAGNOSTICS

25.38.1 BUSINESS OVERVIEW

25.38.2 PRODUCT OFFERINGS

25.39 EDAN INSTRUMENTS

25.39.1 BUSINESS OVERVIEW

25.39.2 PRODUCT OFFERINGS

25.40 EKF DIAGNOSTICS HOLDING

25.40.1 BUSINESS OVERVIEW

25.40.2 PRODUCT OFFERINGS

25.41 ELITECHGROUP

25.41.1 BUSINESS OVERVIEW

25.41.2 PRODUCT OFFERINGS

25.42 ERBA DIAGNOSTICS

25.42.1 BUSINESS OVERVIEW

25.42.2 PRODUCT OFFERINGS

25.43 GENETRON HOLDINGS

25.43.1 BUSINESS OVERVIEW

25.43.2 PRODUCT OFFERINGS

25.44 GENRUI BIOTECH

25.44.1 BUSINESS OVERVIEW

25.44.2 PRODUCT OFFERINGS

25.45 HOLOGIC

25.45.1 BUSINESS OVERVIEW

25.45.2 PRODUCT OFFERINGS

25.46 HIGH TECHNOLOGY

25.46.1 BUSINESS OVERVIEW

25.46.2 PRODUCT OFFERINGS

25.47 HORIBA

25.47.1 BUSINESS OVERVIEW

25.47.2 PRODUCT OFFERINGS

25.48 LINEAR CHEMICALS

25.48.1 BUSINESS OVERVIEW

25.48.2 PRODUCT OFFERINGS

25.49 ILLUMINA

25.49.1 BUSINESS OVERVIEW

25.49.2 PRODUCT OFFERINGS

25.50 INTEC

25.50.1 BUSINESS OVERVIEW

25.50.2 PRODUCT OFFERINGS

25.51 J. MITRA & CO.

25.51.1 BUSINESS OVERVIEW

25.51.2 PRODUCT OFFERINGS

25.52 KILPEST INDIA LIMITED

25.52.1 BUSINESS OVERVIEW

25.52.2 PRODUCT OFFERINGS

25.53 MACCURA BIOTECHNOLOGY

25.53.1 BUSINESS OVERVIEW

25.53.2 PRODUCT OFFERINGS

25.54 MEDSOURCE OZONE BIOMEDICALS

25.54.1 BUSINESS OVERVIEW

25.54.2 PRODUCT OFFERINGS

25.55 MERIL LIFE SCIENCES

25.55.1 BUSINESS OVERVIEW

25.55.2 PRODUCT OFFERINGS

25.56 MP BIOMEDICALS

25.56.1 BUSINESS OVERVIEW

25.56.2 PRODUCT OFFERINGS

25.57 NANJING SYNTHGENE MEDICAL TECHNOLOGY

25.57.1 BUSINESS OVERVIEW

25.57.2 PRODUCT OFFERINGS

25.58 NIHON KOHDEN

25.58.1 BUSINESS OVERVIEW

25.58.2 PRODUCT OFFERINGS

25.59 NORMA INSTRUMENTS

25.59.1 BUSINESS OVERVIEW

25.59.2 PRODUCT OFFERINGS

25.60 NOWDIAGNOSTICS

25.60.1 BUSINESS OVERVIEW

25.60.2 PRODUCT OFFERINGS

25.61 ORTHO CLINICAL DIAGNOSTICS

25.61.1 BUSINESS OVERVIEW

25.61.2 PRODUCT OFFERINGS

25.62 OPKO HEALTH (BIOREFERENCE HEALTH)

25.62.1 BUSINESS OVERVIEW

25.62.2 PRODUCT OFFERINGS

25.63 ORASURE TECHNOLOGIES

25.63.1 BUSINESS OVERVIEW

25.63.2 PRODUCT OFFERINGS

25.64 PERKIN ELMER

25.64.1 BUSINESS OVERVIEW

25.64.2 PRODUCT OFFERINGS

25.65 PRESTIGE DIAGNOSTICS

25.65.1 BUSINESS OVERVIEW

25.65.2 PRODUCT OFFERINGS

25.66 QIAGEN

25.66.1 BUSINESS OVERVIEW

25.66.2 PRODUCT OFFERINGS

25.67 QUIDEL

25.67.1 BUSINESS OVERVIEW

25.67.2 PRODUCT OFFERINGS

25.68 SYSMEX

25.68.1 BUSINESS OVERVIEW

25.68.2 PRODUCT OFFERINGS

25.69 SALOFA OY

25.69.1 BUSINESS OVERVIEW

25.69.2 PRODUCT OFFERINGS

25.70 SEASUN BIOMATERIALS

25.70.1 BUSINESS OVERVIEW

25.70.2 PRODUCT OFFERINGS

25.71 SEKISUI DIAGNOSTICS

25.71.1 BUSINESS OVERVIEW

25.72 SFRI

25.72.1 BUSINESS OVERVIEW

25.72.2 PRODUCT OFFERINGS

25.73 SHENZHEN DYMIND BIOTECHNOLOGY

25.73.1 BUSINESS OVERVIEW

25.73.2 PRODUCT OFFERINGS

25.74 SHENZHEN ICUBIO BIOMEDICAL TECHNOLOGY

25.74.1 BUSINESS OVERVIEW

25.74.2 PRODUCT OFFERINGS

25.75 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS

25.75.1 BUSINESS OVERVIEW

25.75.2 PRODUCT OFFERINGS

25.76 SHENZHEN PROKAN ELECTRONICS

25.76.1 BUSINESS OVERVIEW

25.76.2 PRODUCT OFFERINGS

25.77 SHENZHEN LANDWIND MEDICAL

25.77.1 BUSINESS OVERVIEW

25.77.2 PRODUCT OFFERINGS

25.78 SINOCARE

25.78.1 BUSINESS OVERVIEW

25.78.2 PRODUCT OFFERINGS

25.79 SPINREACT

25.79.1 BUSINESS OVERVIEW

25.79.2 PRODUCT OFFERINGS

25.80 SURESCREEN DIAGNOSTICS

25.80.1 BUSINESS OVERVIEW

25.80.2 PRODUCT OFFERINGS

25.81 THE BINDING SITE GROUP

25.81.1 BUSINESS OVERVIEW

25.81.2 PRODUCT OFFERINGS

25.82 TRINITY BIOTECH

25.82.1 BUSINESS OVERVIEW

25.82.2 PRODUCT OFFERINGS

25.83 TRIVITRON HEALTHCARE

25.83.1 BUSINESS OVERVIEW

25.83.2 PRODUCT OFFERINGS

25.84 XIAMEN BIOTIME BIOTECHNOLOGY

25.84.1 BUSINESS OVERVIEW

25.84.2 PRODUCT OFFERINGS

25.85 ZHEJIANG ORIENT GENE BIOTECH

25.85.1 BUSINESS OVERVIEW

25.85.2 PRODUCT OFFERINGS

 

26 REPORT SUMMARY

26.1 KEY TAKEAWAYS

26.2 STRATEGIC RECOMMENDATIONS

 

27 QUANTITATIVE SUMMARY

27.1 MARKET BY GEOGRAPHY

27.2 MARKET BY PRODUCT & SERVICES

27.3 MARKET BY TECHNOLOGY

27.4 MARKET BY APPLICATION

27.5 MARKET BY END-USERS

27.6 PRODUCT & SERVICES: MARKET BY GEOGRAPHY

27.6.1 REAGENTS & CONSUMABLES: MARKET BY GEOGRAPHY

27.6.2 INSTRUMENTS/ANALYZERS & SOFTWARE: MARKET BY GEOGRAPHY

27.6.3 SERVICES: MARKET BY GEOGRAPHY

27.7 TECHNOLOGY: MARKET BY GEOGRAPHY

27.7.1 IMMUNO & CLINICAL CHEMISTRY: MARKET BY GEOGRAPHY

27.7.2 MOLECULAR DIAGNOSTICS: MARKET BY GEOGRAPHY

27.7.3 HEMATOLOGY: MARKET BY GEOGRAPHY

27.7.4 MICROBIOLOGY & CYTOLOGY: MARKET BY GEOGRAPHY

27.7.5 OTHER TECHNOLOGIES: MARKET BY GEOGRAPHY

27.8 APPLICATION: MARKET BY GEOGRAPHY

27.8.1 INFECTIOUS DISEASES: MARKET BY GEOGRAPHY

27.8.2 DIABETES: MARKET BY GEOGRAPHY

27.8.3 CARDIOLOGY: MARKET BY GEOGRAPHY

27.8.4 ONCOLOGY: MARKET BY GEOGRAPHY

27.8.5 AUTOIMMUNE DISEASES: MARKET BY GEOGRAPHY

27.8.6 NEPHROLOGY: MARKET BY GEOGRAPHY

27.8.7 DRUG TESTING: MARKET BY GEOGRAPHY

27.8.8 OTHER APPLICATIONS: MARKET BY GEOGRAPHY

27.9 END-USERS: MARKET BY GEOGRAPHY

27.9.1 STANDARD REFERENCE LABS: MARKET BY GEOGRAPHY

27.9.2 HOSPITAL AFFILIATED LABS: MARKET BY GEOGRAPHY

27.9.3 INDIVIDUALS: MARKET BY GEOGRAPHY

27.9.4 CLINICS: MARKET BY GEOGRAPHY

27.9.5 OTHER END-USERS: MARKET BY GEOGRAPHY

 

28 APPENDIX

28.1 ABBREVIATIONS

 LIST OF EXHIBITS

EXHIBIT 1 SEGMENTATION OF GLOBAL IN-VITRO DIAGNOSTICS MARKET

EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2022

EXHIBIT 3 CURRENT & EMERGING MARKET TRENDS

EXHIBIT 4 GLOBAL IN-VITRO DIAGNOSTICS MARKET SEGMENTATION

EXHIBIT 5 MAJOR TRENDS IN IN-VITRO DIAGNOSTICS INDUSTRY

EXHIBIT 6 IMPACT OF ADVANCES IN MOLECULAR DIAGNOSTICS TRANSFORMING THE FUTURE OF HEALTHCARE

EXHIBIT 7 IMPACT OF INCREASED DEMAND FOR COMPANION DIAGNOSTICS IN IVD

EXHIBIT 8 SOME OF THE KEY TECHNOLOGY TRENDS IN COMPANION DIAGNOSTICS

EXHIBIT 9 IMPACT OF INCREASING PRODUCT LAUNCHES & MERGERS & ACQUISITIONS IN IVD

EXHIBIT 10 IMPACT OF PRESENCE OF A SIGNIFICANT PATIENT POPULATION

EXHIBIT 11 CANCER NEW CASES STATISTICS 2020 BY REGIONS

EXHIBIT 12 GLOBAL RARE DISEASES STATISTICS OVERVIEW

EXHIBIT 13 IMPACT OF ADOPTION OF ADVANCED TECHNOLOGIES IN IVD

EXHIBIT 14 CLINICAL LABORATORY ENGAGEMENT WITH AI 2018

EXHIBIT 15 IMPACT OF COVID-19 IMPACTS ON IVD ACCEPTANCE

EXHIBIT 16 UNICEF SARS-COV-2 RRT-PCR TEST FOR AUTOMATED USE 2020 SEPTEMBER -2021 (MILLION)

EXHIBIT 17 IMPACT OF STRINGENT REGULATION AND ASSOCIATED CHALLENGES

EXHIBIT 18 IMPACT OF HIGH COST OF IVD

EXHIBIT 19 IMPACT OF LACK OF ACCESS TO DIAGNOSTIC SERVICES AND ASSOCIATED CHALLENGES

EXHIBIT 20 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022-2028

EXHIBIT 21 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022-2028

EXHIBIT 22 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022-2028

EXHIBIT 23 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY END-USERS 2022-2028

EXHIBIT 24 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028

EXHIBIT 25 GLOBAL IN-VITRO DIAGNOSTICS MARKET 2022–2028 ($ BILLION)

EXHIBIT 26 FIVE FORCES ANALYSIS 2022

EXHIBIT 27 INCREMENTAL GROWTH BY PRODUCT &SERVICES 2022 & 2028

EXHIBIT 28 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022-2028

EXHIBIT 29 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY PRODUCTS & SERVICES: MARKET OVERVIEW

EXHIBIT 30 GLOBAL IVD MARKET BY PRODUCTS & SERVICES: INCREMENTAL GROWTH

EXHIBIT 31 GLOBAL IVD MARKET BY PRODUCTS & SERVICES: ABSOLUTE GROWTH

EXHIBIT 32 GLOBAL IVD MARKET BY REAGENTS & CONSUMABLES: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 33 GLOBAL IVD MARKET BY REAGENTS & CONSUMABLES 2022–2028 ($ BILLION)

EXHIBIT 34 GLOBAL IVD MARKET BY INSTRUMENT/ANALYZERS & SOFTWARE: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 35 GLOBAL IVD MARKET BY INSTRUMENTS/ ANALYZERS & SOFTWARE 2022–2028 ($ BILLION)

EXHIBIT 36 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY SERVICES: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 37 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY SERVICES 2022–2028 ($ BILLION)

EXHIBIT 38 INCREMENTAL GROWTH BY TECHNOLOGY 2022 & 2028

EXHIBIT 39 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022-2028

EXHIBIT 40 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY: MARKET OVERVIEW

EXHIBIT 41 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY: INCREMENTAL GROWTH

EXHIBIT 42 GLOBAL IVD MARKET BY TECHNOLOGY: ABSOLUTE GROWTH

EXHIBIT 43 DIABETES ESTIMATED & PROJECTED PATIENT POPULATION: OPPORTUNITIES FOR SELF-MONITORING TEST

EXHIBIT 44 GLOBAL IVD MARKET BY IMMUNO & CLINICAL CHEMISTRY: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 45 GLOBAL IVD MARKET BY IMMUNO & CLINICAL CHEMISTRY 2022–2028 ($ BILLION)

EXHIBIT 46 GLOBAL IVD MARKET BY MOLECULAR DIAGNOSTICS: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 47 GLOBAL IVD MARKET BY MOLECULAR DIAGNOSTICS 2022–2028 ($ BILLION)

EXHIBIT 48 GLOBAL IVD MARKET BY HEMATOLOGY: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 49 GLOBAL IVD MARKET BY HEMATOLOGY 2022–2028 ($ BILLION)

EXHIBIT 50 COMPARISON OF CURRENT & DEVELOPING DIAGNOSTICS BY COST & COMPLEXITY 2021

EXHIBIT 51 GLOBAL IVD MARKET BY MICROBIOLOGY & CYTOLOGY: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 52 GLOBAL IVD MARKET BY MICROBIOLOGY & CYTOLOGY 2022–2028 ($ BILLION)

EXHIBIT 53 SYSMEX CORPORATION HEMOSTASIS BUSINESS SALE 2018 TO 2021 ($ BILLION)

EXHIBIT 54 ADVANTAGES OF URINALYSIS OVER BLOOD TESTING

EXHIBIT 55 GLOBAL IVD MARKET BY OTHER TECHNOLOGIES: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 56 GLOBAL IVD MARKET BY OTHER TECHNOLOGY 2022–2028 ($ BILLION)

EXHIBIT 57 INCREMENTAL GROWTH BY APPLICATIONS 2022 & 2028

EXHIBIT 58 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022-2028

EXHIBIT 59 GLOBAL IVD MARKET BY APPLICATION: MARKET OVERVIEW

EXHIBIT 60 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY APPLICATION: INCREMENTAL GROWTH

EXHIBIT 61 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY APPLICATION: ABSOLUTE GROWTH

EXHIBIT 62 DAILY COVID-19 CASES 2020-2022

EXHIBIT 63 HIV PATIENT POPULATION BY REGION 2021 (MILLION)

EXHIBIT 64 GLOBAL IVD MARKET BY INFECTIOUS DISEASES: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 65 GLOBAL IVD MARKET BY INFECTIOUS DISEASES 2022–2028 ($ BILLION)

EXHIBIT 66 NO. OF PEOPLE WITH DIABETES & PER IDF REGION 2021-2045 (20-79 YEARS)

EXHIBIT 67 DIABETES PREVALENCE BY INCOME OF COUNTRIES 2021 & 2025

EXHIBIT 68 GLOBAL IVD MARKET BY DIABETES: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 69 GLOBAL IVD MARKET BY DIABETES 2022–2028 ($ BILLION)

EXHIBIT 70 GLOBAL IVD MARKET BY CARDIOLOGY: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 71 GLOBAL IVD MARKET BY CARDIOLOGY 2022–2028 ($ BILLION)

EXHIBIT 72 NEW CANCER CASES BY TYPE 2020

EXHIBIT 73 GLOBAL IVD MARKET BY ONCOLOGY: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 74 GLOBAL IVD MARKET BY ONCOLOGY 2022–2028 ($ BILLION)

EXHIBIT 75 GLOBAL IVD MARKET BY AUTOIMMUNE DISEASES: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 76 GLOBAL IVD MARKET BY AUTOIMMUNE DISEASES 2022–2028 ($ BILLION)

EXHIBIT 77 GLOBAL EPIDEMIOLOGY OF CHRONIC KIDNEY DISEASE (CKD): AN UPDATE 2022

EXHIBIT 78 GLOBAL IVD MARKET BY NEPHROLOGY: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 79 GLOBAL IVD MARKET BY NEPHROLOGY 2022–2028 ($ BILLION)

EXHIBIT 80 COMPARISON OF RAPID & LAB-BASED DRUG SCREENING IN URINE SAMPLE BASED ON TURNAROUND TIME (MINUTES)

EXHIBIT 81 GLOBAL IVD MARKET BY DRUG TESTING: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 82 GLOBAL IVD MARKET BY DRUG TESTING 2022–2028 ($ BILLION)

EXHIBIT 83 GLOBAL IVD MARKET BY OTHER APPLICATIONS: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 84 GLOBAL IVD MARKET BY OTHER APPLICATION 2022–2028 ($ BILLION)

EXHIBIT 85 INCREMENTAL GROWTH BY END-USERS 2022 & 2028

EXHIBIT 86 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY END-USERS 2022-2028

EXHIBIT 87 GLOBAL IVD MARKET BY END-USERS: MARKET OVERVIEW

EXHIBIT 88 GLOBAL IVD MARKET BY END-USERS: INCREMENTAL GROWTH

EXHIBIT 89 GLOBAL IVD MARKET BY END-USER: ABSOLUTE GROWTH

EXHIBIT 90 GLOBAL IVD MARKET BY STANDARD REFERENCE LABS: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 91 GLOBAL IVD MARKET BY STANDARD REFERENCE LABS 2022–2028 ($ BILLION)

EXHIBIT 92 GLOBAL IVD MARKET BY HOSPITAL AFFILIATED LABS: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 93 GLOBAL IVD MARKET BY HOSPITAL AFFILIATED LABS 2022–2028 ($ BILLION)

EXHIBIT 94 GLOBAL IVD MARKET BY INDIVIDUAL: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 95 GLOBAL IVD MARKET BY INDIVIDUALS 2022–2028 ($ BILLION)

EXHIBIT 96 GLOBAL IVD MARKET BY CLINICS: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 97 GLOBAL IVD MARKET BY CLINICS 2022–2028 ($ BILLION)

EXHIBIT 98 GLOBAL IVD MARKET BY OTHER END-USERS: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 99 GLOBAL IVD MARKET BY OTHER END-USERS 2022–2028 ($ BILLION)

EXHIBIT 100 INCREMENTAL GROWTH BY GEOGRAPHY 2022 & 2028

EXHIBIT 101 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028

EXHIBIT 102 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY: MARKET OVERVIEW

EXHIBIT 103 PRODUCT LIFE CYCLE IN VARIOUS REGIONS – IVD MARKET

EXHIBIT 104 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY: INCREMENTAL GROWTH

EXHIBIT 105 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY: ABSOLUTE GROWTH

EXHIBIT 106 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET: KEY COUNTRIES

EXHIBIT 107 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 108 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET 2022–2028 ($ BILLION)

EXHIBIT 109 INCREMENTAL GROWTH IN NORTH AMERICA 2022 & 2028

EXHIBIT 110 US: HEALTH CONDITIONS & PREVALENCE 2019 TO 2022

EXHIBIT 111 IN-VITRO DIAGNOSTICS MARKET IN THE US 2022–2028 ($ BILLION)

EXHIBIT 112 IN-VITRO DIAGNOSTICS MARKET IN CANADA 2022–2028 ($ BILLION)

EXHIBIT 113 EUROPE IN-VITRO DIAGNOSTICS MARKET: KEY COUNTRIES

EXHIBIT 114 POTENTIAL EFFECT OF IVDR ON LDTS IN CLINICAL LABS

EXHIBIT 115 EUROPE IN-VITRO DIAGNOSTICS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 116 EUROPE IN-VITRO DIAGNOSTICS MARKET 2022–2028 ($ BILLION)

EXHIBIT 117 INCREMENTAL GROWTH IN EUROPE 2022 & 2028

EXHIBIT 118 GERMANY: PEOPLE LIVING WITH HIV AND NEW HIV INFECTION CASES 2015 TO 2020

EXHIBIT 119 IN-VITRO DIAGNOSTICS MARKET IN GERMANY 2022–2028 ($ BILLION)

EXHIBIT 120 IN-VITRO DIAGNOSTICS MARKET IN FRANCE 2022-2028 ($ BILLION)

EXHIBIT 121 IN-VITRO DIAGNOSTICS MARKET IN RUSSIA 2022–2028 ($ BILLION)

EXHIBIT 122 IN-VITRO DIAGNOSTICS MARKET IN SPAIN 2022–2028 ($ BILLION)

EXHIBIT 123 IN-VITRO DIAGNOSTICS MARKET IN ITALY 2022–2028 ($ BILLION)

EXHIBIT 124 IN-VITRO DIAGNOSTICS MARKET IN THE UK 2022–2028 ($ BILLION)

EXHIBIT 125 APAC IN-VITRO DIAGNOSTICS MARKET: KEY COUNTRIES

EXHIBIT 126 APAC IN-VITRO DIAGNOSTICS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 127 APAC IN-VITRO DIAGNOSTICS MARKET 2022–2028 ($ BILLION)

EXHIBIT 128 INCREMENTAL GROWTH IN APAC 2022 & 2028

EXHIBIT 129 IN-VITRO DIAGNOSTICS MARKET IN CHINA 2022–2028 ($ BILLION)

EXHIBIT 130 IN-VITRO DIAGNOSTICS MARKET JAPAN 2022–2028 ($ BILLION)

EXHIBIT 131 IN-VITRO DIAGNOSTICS MARKET IN INDIA 2022–2028 ($ BILLION)

EXHIBIT 132 IN-VITRO DIAGNOSTICS MARKET IN SOUTH KOREA 2022–2028 ($ BILLION)

EXHIBIT 133 IN-VITRO DIAGNOSTICS MARKET IN AUSTRALIA 2022–2028 ($ BILLION)

EXHIBIT 134 TOTAL HIV CASES IN INDONESIA 2010-2021

EXHIBIT 135 IN-VITRO DIAGNOSTICS MARKET IN INDONESIA 2022–2028 ($ BILLION)

EXHIBIT 136 IN-VITRO DIAGNOSTICS MARKET IN MALAYSIA 2022–2028 ($ BILLION)

EXHIBIT 137 IN-VITRO DIAGNOSTICS MARKET IN SINGAPORE 2022–2028 ($ BILLION)

EXHIBIT 138 LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET: KEY COUNTRIES

EXHIBIT 139 LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 140 LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET 2022–2028 ($ BILLION)

EXHIBIT 141 INCREMENTAL GROWTH IN LATIN AMERICA 2022 & 2028

EXHIBIT 142 IN-VITRO DIAGNOSTICS MARKET IN BRAZIL 2022–2028 ($ BILLION)

EXHIBIT 143 IN-VITRO DIAGNOSTICS MARKET MEXICO 2022–2028 ($ BILLION)

EXHIBIT 144 IN-VITRO DIAGNOSTICS MARKET ARGENTINA 2022–2028 ($ BILLION)

EXHIBIT 145 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET: KEY COUNTRIES

EXHIBIT 146 MIDDLE EAST & AFRICA NATIONAL HIVST POLICY & IMPLEMENTATION 2020

EXHIBIT 147 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 148 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET 2022–2028 ($ BILLION)

EXHIBIT 149 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2022 & 2028

EXHIBIT 150 IN-VITRO DIAGNOSTICS MARKET IN TURKEY 2022–2028 ($ BILLION)

EXHIBIT 151 IN-VITRO DIAGNOSTICS MARKET SAUDI ARABIA 2022–2028 ($ BILLION)

EXHIBIT 152 IN-VITRO DIAGNOSTICS MARKET SOUTH AFRICA 2022–2028 ($ BILLION)

EXHIBIT 153 GLOBAL IVD MARKET DOMINANCE ANALYSIS

EXHIBIT 154 GLOBAL IVD MARKET DOMINANCE ANALYSIS

EXHIBIT 155 VENDORS OFFERING IVD SOLUTIONS: CAPABILITIES & EXPERTISE ASSESSMENT

EXHIBIT 156 MARKET SHARE & PENETRATION ANALYSIS BASED ON THE REVENUE OF THE MARKET PLAYERS 2020

 

 

LIST OF TABLES

TABLE 1 KEY CAVEATS

TABLE 2 CURRENCY CONVERSION 2015−2022

TABLE 3 LIST OF APPROVED/CLEARED COMPANION DIAGNOSTIC DEVICES (IVD)

TABLE 4 LEADING COMPANIES WITH NEW IVD PRODUCTS LAUNCHED 2021-2022

TABLE 5 LEADING COMPANIES WITH NEW IVD PRODUCTS LAUNCHED 2021-2022

TABLE 6 SARS-COV-2 DIAGNOSTICS TEST TYPE

TABLE 7 GLOBAL IVD REAGENTS AND CONSUMABLES MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 8 GLOBAL IVD REAGENTS AND CONSUMABLES MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 9 GLOBAL IVD INSTRUMENTS/ANALYZERS & SOFTWARE MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 10 GLOBAL IVD INSTRUMENTS/ANALYZERS & SOFTWARE MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 11 GLOBAL IVD SERVICES MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 12 GLOBAL IVD SERVICES MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 13 GLOBAL IVD IMMUNO & CLINICAL CHEMISTRY MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 14 GLOBAL IVD IMMUNO & CLINICAL CHEMISTRY MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 15 GLOBAL IVD MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 16 GLOBAL IVD MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 17 GLOBAL IVD HEMATOLOGY MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 18 GLOBAL IVD HEMATOLOGY MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 19 GLOBAL IVD MICROBIOLOGY & CYTOLOGY MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 20 GLOBAL IVD MICROBIOLOGY & CYTOLOGY MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 21 GLOBAL IVD OTHERS TECHNOLOGY MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 22 GLOBAL IVD OTHERS TECHNOLOGY MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 23 COVID-19 PATIENT POPULATION & TOTAL TEST PERFORMED 2020-2022

TABLE 24 GLOBAL IVD INFECTIOUS DISEASES MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 25 GLOBAL IVD INFECTIOUS DISEASES MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 26 UNDIAGNOSED DIABETES PATIENT POPULATION CLASSIFICATION BASED ON ECONOMIC STATUS OF COUNTRIES 2021

TABLE 27 GLOBAL IVD DIABETES MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 28 GLOBAL IVD DIABETES MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 29 GLOBAL IVD CARDIOLOGY MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 30 GLOBAL IVD CARDIOLOGY MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 31 GLOBAL IVD ONCOLOGY MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 32 GLOBAL IVD ONCOLOGY MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 33 GLOBAL IVD AUTOIMMUNE DISEASES MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 34 GLOBAL IVD AUTOIMMUNE DISEASES MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 35 GLOBAL CHRONIC KIDNEY FAILURE PATIENT POPULATION

TABLE 36 GLOBAL IVD NEPHROLOGY MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 37 GLOBAL IVD NEPHROLOGY MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 38 GLOBAL IVD DRUG TESTING MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 39 GLOBAL IVD DRUG TESTING MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 40 GLOBAL IVD OTHER APPLICATIONS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 41 GLOBAL IVD OTHER APPLICATIONS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 42 GLOBAL IVD STANDARD REFERENCE LABS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 43 GLOBAL IVD STANDARD REFERENCE LABS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 44 GLOBAL IVD HOSPITAL AFFILIATED LABS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 45 GLOBAL IVD HOSPITAL AFFILIATED LABS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 46 GLOBAL IVD INDIVIDUALS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 47 GLOBAL IVD INDIVIDUALS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 48 GLOBAL IVD CLINICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 49 GLOBAL IVD CLINICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 50 GLOBAL IVD OTHER END-USERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 51 GLOBAL IVD OTHER END-USERS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 52 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 ($ BILLION)

TABLE 53 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 (%)

TABLE 54 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 ($ BILLION)

TABLE 55 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 (%)

TABLE 56 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022−2028 ($ BILLION)

TABLE 57 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022−2028 (%)

TABLE 58 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022−2028 ($ BILLION)

TABLE 59 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022−2028 (%)

TABLE 60 US: CANCER STATISTICS 2020

TABLE 61 EUROPE IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 ($ BILLION)

TABLE 62 EUROPE IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 (%)

TABLE 63 EUROPE IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 ($ BILLION)

TABLE 64 EUROPE IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 (%)

TABLE 65 EUROPE IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022−2028 ($ BILLION)

TABLE 66 EUROPE IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022−2028 (%)

TABLE 67 EUROPE IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022−2028 ($ BILLION)

TABLE 68 EUROPE IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022−2028 (%)

TABLE 69 APAC IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 ($ BILLION)

TABLE 70 APAC IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 (%)

TABLE 71 APAC IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 ($ BILLION)

TABLE 72 APAC IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 (%)

TABLE 73 APAC IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022−2028 ($ BILLION)

TABLE 74 APAC IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022−2028 (%)

TABLE 75 APAC IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022−2028 ($ BILLION)

TABLE 76 APAC IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022−2028 (%)

TABLE 77 COMMERCIAL RT-PCR ASSAY FOR SARS-COV-2 DIAGNOSIS IN MALAYSIA

TABLE 78 COVID-19 STATISTICS IN LATIN AMERICA (2019-2022)

TABLE 79 LATIN IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 ($ BILLION)

TABLE 80 LATIN IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 (%)

TABLE 81 LATIN IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 ($ BILLION)

TABLE 82 LATIN IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 (%)

TABLE 83 LATIN IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022−2028 ($ BILLION)

TABLE 84 LATIN IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022−2028 (%)

TABLE 85 LATIN IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022−2028 ($ BILLION)

TABLE 86 LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022−2028 (%)

TABLE 87 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 ($ BILLION)

TABLE 88 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 (%)

TABLE 89 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 ($ BILLION)

TABLE 90 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 (%)

TABLE 91 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022−2028 ($ BILLION)

TABLE 92 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022−2028 (%)

TABLE 93 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022−2028 ($ BILLION)

TABLE 94 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022−2028 (%)

TABLE 95 COMPETITION AMONG MARKET PLAYERS BASED ON TECHNOLOGY

TABLE 96 COMPETITION AMONG MARKET PLAYERS BASED ON TECHNOLOGY ($ BILLION) 2020-2021

TABLE 97 ABBOTT DIAGNOSTIC SEGMENT REVENUE FROM 2019 – 2021 ($ MILLION)

TABLE 98 ABBOTT: MAJOR PRODUCT OFFERINGS

TABLE 99 DANAHER: MAJOR PRODUCT OFFERINGS

TABLE 100 F. HOFFMANN-LA ROCHE: MAJOR PRODUCT OFFERINGS

TABLE 101 SIEMENS HEALTHINEERS: MAJOR PRODUCT OFFERINGS

TABLE 102 THERMO FISHER SCIENTIFIC: MAJOR PRODUCT OFFERINGS

TABLE 103 ATOMO DIAGNOSTICS: MAJOR PRODUCT OFFERINGS

TABLE 104 ACCELERATE DIAGNOSTICS: MAJOR PRODUCT OFFERINGS

TABLE 105 AGILENT TECHNOLOGIES: MAJOR PRODUCT OFFERINGS

TABLE 106 ALTONA DIAGNOSTICS: MAJOR PRODUCT OFFERINGS

TABLE 107 AMOY DIAGNOSTICS: MAJOR PRODUCT OFFERINGS

TABLE 108 ARKRAY: MAJOR PRODUCT OFFERINGS

TABLE 109 ACCUBIOTECH: MAJOR PRODUCT OFFERINGS

TABLE 110 AGAPPE DIAGNOSTICS: MAJOR PRODUCT OFFERINGS

TABLE 111 BD: MAJOR PRODUCT OFFERINGS

TABLE 112 BIO-RAD LABORATORIES: MAJOR PRODUCT OFFERINGS

TABLE 113 BALIO DIAGNOSTICS: MAJOR PRODUCT OFFERINGS

TABLE 114 B&E BIO-TECHNOLOGY: MAJOR PRODUCT OFFERINGS

TABLE 115 BIOMÉRIEUX: MAJOR PRODUCT OFFERINGS

TABLE 116 BIOLYTICAL LABORATORIES: MAJOR PRODUCT OFFERINGS

TABLE 117 BIOSYNEX: MAJOR PRODUCT OFFERINGS

TABLE 118 BIOCARTIS: MAJOR PRODUCT OFFERINGS

TABLE 119 BIOCEPT: MAJOR PRODUCT OFFERINGS

TABLE 120 BIOHIT OYJ: MAJOR PRODUCT OFFERINGS

TABLE 121 BIOMERICA: MAJOR PRODUCT OFFERINGS

TABLE 122 BIOSYSTEMS: MAJOR PRODUCT OFFERINGS

TABLE 123 BIOWAY BIOLOGICAL TECHNOLOGY: MAJOR PRODUCT OFFERINGS

TABLE 124 BOULE DIAGNOSTICS: MAJOR PRODUCT OFFERINGS

TABLE 125 CUPID LIMITED: MAJOR PRODUCT OFFERINGS

TABLE 126 CAREDX: MAJOR PRODUCT OFFERINGS

TABLE 127 CHEMBIO DIAGNOSTICS: MAJOR PRODUCT OFFERINGS

TABLE 128 CLINDIAG SYSTEMS: MAJOR PRODUCT OFFERINGS

TABLE 129 CONTEC MEDICAL SYSTEMS: MAJOR PRODUCT OFFERINGS

TABLE 130 CONVERGENT TECHNOLOGIES: MAJOR PRODUCT OFFERINGS

TABLE 131 CPC DIAGNOSTICS: MAJOR PRODUCT OFFERINGS

TABLE 132 CPM SCIENTIFICA: MAJOR PRODUCT OFFERINGS

TABLE 133 CELLAVISION: MAJOR PRODUCT OFFERINGS

TABLE 134 DIALAB: MAJOR PRODUCT OFFERINGS

TABLE 135 DEXCOM: MAJOR PRODUCT OFFERINGS

TABLE 136 DIASORIN: MAJOR PRODUCT OFFERINGS

TABLE 137 DIAGON: MAJOR PRODUCT OFFERINGS

TABLE 138 DIATRON: MAJOR PRODUCT OFFERINGS

TABLE 139 DIRUI: MAJOR PRODUCT OFFERINGS

TABLE 140 DRUCKER DIAGNOSTICS: MAJOR PRODUCT OFFERINGS

TABLE 141 EDAN INSTRUMENTS: MAJOR PRODUCT OFFERINGS

TABLE 142 EKF DIAGNOSTICS HOLDINGS: MAJOR PRODUCT OFFERINGS

TABLE 143 ELITECHGROUP: MAJOR PRODUCT OFFERINGS

TABLE 144 ERBA DIAGNOSTICS: MAJOR PRODUCT OFFERINGS

TABLE 145 GENETRON HOLDINGS: MAJOR PRODUCT OFFERINGS

TABLE 146 GENRUI BIOTECH: MAJOR PRODUCT OFFERINGS

TABLE 147 HOLOGIC: MAJOR PRODUCT OFFERINGS

TABLE 148 HIGH TECHNOLOGY: MAJOR PRODUCT OFFERINGS

TABLE 149 HORIBA: MAJOR PRODUCT OFFERINGS

TABLE 150 LINEAR CHEMICALS: MAJOR PRODUCT OFFERINGS

TABLE 151 ILLUMINA: MAJOR PRODUCT OFFERINGS

TABLE 152 INTEC: MAJOR PRODUCT OFFERINGS

TABLE 153 J. MITRA & CO.: MAJOR PRODUCT OFFERINGS

TABLE 154 KILPEST INDIA LIMITED: MAJOR PRODUCT OFFERINGS

TABLE 155 MACCURA BIOTECHNOLOGY: MAJOR PRODUCT OFFERINGS

TABLE 156 MEDSOURCE OZONE BIOMEDICALS: MAJOR PRODUCT OFFERINGS

TABLE 157 MERIL LIFE SCIENCES: MAJOR PRODUCT OFFERINGS

TABLE 158 MP BIOMEDICALS: MAJOR PRODUCT OFFERINGS

TABLE 159 NANJING SYNTHGENE MEDICAL TECHNOLOGY: MAJOR PRODUCT OFFERINGS

TABLE 160 NIHON KOHDEN: MAJOR PRODUCT OFFERINGS

TABLE 161 NORMA INSTRUMENTS: MAJOR PRODUCT OFFERINGS

TABLE 162 NOWDIAGNOSTICS: MAJOR PRODUCT OFFERINGS

TABLE 163 ORTHO CLINICAL DIAGNOSTICS: MAJOR PRODUCT OFFERINGS

TABLE 164 OPKO HEALTH: MAJOR PRODUCT OFFERINGS

TABLE 165 ORASURE TECHNOLOGIES: MAJOR PRODUCT OFFERINGS

TABLE 166 PERKIN ELMER: MAJOR PRODUCT OFFERINGS

TABLE 167 PRESTIGE DIAGNOSTICS: MAJOR PRODUCT OFFERINGS

TABLE 168 QIAGEN: MAJOR PRODUCT OFFERINGS

TABLE 169 QUIDEL: MAJOR PRODUCT OFFERINGS

TABLE 170 SYSMEX: MAJOR PRODUCT OFFERINGS

TABLE 171 SALOFA OY: MAJOR PRODUCT OFFERINGS

TABLE 172 SEASUN BIOMATERIALS: MAJOR PRODUCT OFFERINGS

TABLE 173 SEKISUI DIAGNOSTICS: MAJOR PRODUCT OFFERINGS

TABLE 174 SFRI: MAJOR PRODUCT OFFERINGS

TABLE 175 SHENZHEN DYMIND BIOTECHNOLOGY: MAJOR PRODUCT OFFERINGS

TABLE 176 SHENZHEN ICUBIO BIOMEDICAL TECHNOLOGY: MAJOR PRODUCT OFFERINGS

TABLE 177 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS: MAJOR PRODUCT OFFERINGS

TABLE 178 SHENZHEN PROKAN ELECTRONICS: MAJOR PRODUCT OFFERINGS

TABLE 179 SHENZHEN LANDWIND MEDICAL: MAJOR PRODUCT OFFERINGS

TABLE 180 SINOCARE: MAJOR PRODUCT OFFERINGS

TABLE 181 SPINREACT: MAJOR PRODUCT OFFERINGS

TABLE 182 SURESCREEN DIAGNOSTICS: MAJOR PRODUCT OFFERINGS

TABLE 183 THE BINDING SITE GROUP: MAJOR PRODUCT OFFERINGS

TABLE 184 TRINITY BIOTECH: MAJOR PRODUCT OFFERINGS

TABLE 185 TRIVITRON HEALTHCARE: MAJOR PRODUCT OFFERINGS

TABLE 186 XIAMEN BIOTIME BIOTECHNOLOGY: MAJOR PRODUCT OFFERINGS

TABLE 187 ZHEJIANG ORIENT GENE BIOTECH: MAJOR PRODUCT OFFERINGS

TABLE 188 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 189 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 190 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 ($ BILLION)

TABLE 191 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 (%)

TABLE 192 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 ($ BILLION)

TABLE 193 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 (%)

TABLE 194 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022−2028 ($ BILLION)

TABLE 195 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 196 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY END-USERS 2022−2028 ($ BILLION)

TABLE 197 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY END-USERS 2022−2028 (%)

TABLE 198 REAGENTS & CONSUMABLES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 199 REAGENTS & CONSUMABLES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 200 INSTRUMENTS/ANALYZERS & SOFTWARE IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 201 INSTRUMENTS/ANALYZERS & SOFTWARE IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 202 SERVICES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 203 SERVICES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 204 IMMUNO & CLINICAL CHEMISTRY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 205 IMMUNO & CLINICAL CHEMISTRY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 206 MOLECULAR DIAGNOSTICS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 207 MOLECULAR DIAGNOSTICS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 208 HEMATOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 209 HEMATOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 210 MICROBIOLOGY & CYTOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 211 MICROBIOLOGY & CYTOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 212 OTHER TECHNOLOGIES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 213 OTHER TECHNOLOGIES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 214 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 215 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 216 DIABETES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 217 DIABETES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 218 CARDIOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 219 CARDIOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 220 ONCOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 221 ONCOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 222 AUTOIMMUNE DISEASES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 223 AUTOIMMUNE DISEASES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 224 NEPHROLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 225 NEPHROLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 226 DRUG TESTING IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 227 DRUG TESTING IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 228 OTHER APPLICATIONS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 229 OTHER APPLICATIONS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 230 STANDARD REFERENCE LABS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 231 STANDARD REFERENCE LABS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 232 HOSPITALS AFFILIATED LABS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 233 HOSPITALS AFFILIATED LABS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 234 INDIVIDUALS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 235 INDIVIDUALS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 236 CLINICS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 237 CLINICS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

TABLE 238 OTHER END-USERS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)

TABLE 239 OTHER END-USERS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)

 

Select a license type that suits your business needs

single-user Single User Licence
$4200.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$4999.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$5999.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$2000.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Licence Types What are these?

Interested in data center portfolio for this report?
Click here

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date